Evidence map›Paper›PMID 29973709›Full record

ReviewNature reviews. Cardiology2018

Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention.

Davide Capodanno, Roxana Mehran, Marco Valgimigli, Usman Baber, Stephan Windecker, Pascal Vranckx, George Dangas, Fabiana Rollini, Takeshi Kimura, Jean-Philippe Collet and 9 more

Open access · hybridAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Cardiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 8 pooled it
24.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 8 syntheses or guidelines pooled it, 211 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2022
    Trial
  10. Clopidogrel monotherapy in patients with and without on-treatment high platelet reactivity: a SMART-CHOICE substudy.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2021
    Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 15 institutions in 7 countries.

Davide CapodannoCardio-Thoracic-Vascular and Transplant Department, Azienda Ospedaliero-Universitaria 'Policlinico-Vittorio Emanuele', Catania, Italy.
Roxana MehranCardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Marco ValgimigliDepartment of Cardiology, Bern University Hospital, Bern, Switzerland.
Usman BaberCardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Stephan WindeckerDepartment of Cardiology, Bern University Hospital, Bern, Switzerland.
Pascal VranckxDepartment of Cardiology and Critical Care Medicine, Faculty of Medicine and Life Sciences University of Hasselt, Hasselt, Belgium.
George DangasCardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Fabiana RolliniUniversity of Florida, College of Medicine, Jacksonville, FL, USA.
Takeshi KimuraDepartment of Neurology, Asahikawa Medical Centre, National Hospital Organization, Asahikawa, Hokkaido, Japan.
Jean-Philippe ColletInstitut De Cardiologie and Action-Coeur Study Group (www.action-coeur.org), Hôpital Pitié-Salpêtrière, Sorbonne Université, Paris, France.
C Michael GibsonDepartment of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Philippe Gabriel StegDépartement Hospitalo-Universitaire FIRE, AP-HP, Hôpital Bichat, Paris, France.
Renato D LopesDuke Clinical Research Institute, Durham, NC, USA.
Hyeon-Cheol GwonDepartment of Internal Medicine, Heart Vascular Stroke Institute, Seoul, Republic of Korea.
Robert F StoreyDepartment of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.
Francesco FranchiUniversity of Florida, College of Medicine, Jacksonville, FL, USA.
Deepak L BhattDepartment of Medicine, Brigham and Women's Hospital Heart & Vascular Center, Boston, MA, USA.
Patrick W SerruysImperial College Healthcare NHS Trust, London, UK.
Dominick J AngiolilloUniversity of Florida, College of Medicine, Jacksonville, FL, USA. dominick.angiolillo@jax.ufl.edu.
Cardiovascular Institute of the South · USFlorida College · USUniversity Hospital of Bern · CHAzienda Ospedaliero-Universitaria Policlinico - Vittorio Emanuele · ITBeth Israel Deaconess Medical Center · USBrigham and Women's Hospital · USClinical Research Institute · USFondation pour l’innovation en Cadiométabolisme et Nutrition · FRHasselt University · BEHôpital Bichat-Claude-Bernard · FRIcahn School of Medicine at Mount Sinai · USImperial College Healthcare NHS Trust · GBNational Hospital Organization · JPUniversity of Florida · USUniversity of Sheffield · GB

Funding

Sparking Advancements in Genomic MedicineU01HG007269 · NHGRI · UNIVERSITY OF FLORIDA · PI CAVALLARI, LARISA HUMMA, JOHNSON, JULIE A. · 2013 to 2024
$17.0M
UF Clinical and Translational Science AwardUL1TR000064 · NCATS · UNIVERSITY OF FLORIDA · PI NELSON, DAVID R · 2012 to 2014
$12.2M
NCATS NIH HHS UL1 TR000064NHGRI NIH HHS U01 HG007269
6 · The paper itself

Abstract

In patients with manifestations of cardiovascular disease, acetylsalicylic acid (popularly known as aspirin) has been the mainstay of treatment for decades owing to its capacity to reduce the risk of ischaemic events. Accordingly, novel antithrombotic therapies have been traditionally tested on a background of acetylsalicylic acid therapy. Although the adjunctive use of such antithrombotic therapies can potentially further reduce the risk of ischaemic events, these agents are also inevitably associated with an increased risk of bleeding. However, acetylsalicylic acid also increases the risk of bleeding, challenging the paradigm that this agent should remain the cornerstone of antiplatelet treatment when alternative antithrombotic agents are also used. Many antithrombotic compounds are characterized by increased potency and consistent efficacy, which might lessen the need for concomitant acetylsalicylic acid. Accordingly, numerous investigations are testing the hypothesis that acetylsalicylic acid-sparing regimens based on newer antithrombotic agents might have an increased net benefit for individual patients owing to the reduction in bleeding risk, without a trade-off in efficacy. This Review summarizes the state of the art relating to antithrombotic approaches with and without acetylsalicylic acid for the prevention of cardiovascular disease and cardioembolic stroke. Discussion of the scientific rationale, from bench to bedside, for ongoing studies of acetylsalicylic acid-free pharmacological strategies is included.

Indexed as

Cardiovascular DiseasesStrokeAspirinFibrinolytic AgentsHumansAspirinFibrinolytic Agents

Identifiers

PMID29973709
OpenAlexW2809722890

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.